首页> 外文期刊>Journal of experimental & clinical cancer research : >Effects of plasma concentrations of 5-fluorouracil on long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma
【24h】

Effects of plasma concentrations of 5-fluorouracil on long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma

机译:血浆中5-氟尿嘧啶浓度对日本食管鳞状细胞癌基于确定性5-氟尿嘧啶/顺铂的放化疗治疗后长期存活的影响

获取原文
           

摘要

Background A substantial body of literature has accumulated during the past 20 years showing the plasma concentrations of 5-fluorouracil (5-FU) to correlate with clinical response and/or toxicity in colorectal cancer, and head and neck cancer, but little information is available concerning effects on long-term survival. Here, Japanese patients with esophageal squamous cell carcinoma (ESCC) were followed up for 5 years after treatment with a definitive 5-FU/cisplatin (CDDP)-based chemoradiotherapy (CRT), and the association between prognosis and the plasma concentration of 5-FU was evaluated. Methods Forty-nine patients with ESCC, who were treated with a definitive 5-FU/CDDP-based CRT, were enrolled. A course consisted of the continuous infusion of 5-FU at 400 mg/m2/day for days 1-5 and 8-12, the infusion of CDDP at 40 mg/m2/day on days 1 and 8, and the radiation at 2 Gy/day on days 1 to 5, 8 to 12, and 15 to 19, with a second course repeated after a 2-week interval. Plasma concentrations of 5-FU were determined by high performance liquid chromatography at 5:00 PM on days 3, 10, 38 and 45, and at 5:00 AM on days 4, 11, 39 and 46. Results The overall 5-year survival rate was 42.9%. Age (P = 0.020), body weight (P = 0.019), and disease stage (P = 0.048) affected the survival, and the survival depended on the clinical response assessed at 1 month after the treatment (P = 0.001). Higher plasma concentrations of 5-FU resulted in a better clinical response (P = 0.043), and trended to prolong survival (P = 0.321). Conclusions The long-term survival after treatment with a definitive 5-FU/CDDP-based CRT possibly depends on the plasma concentrations of 5-FU, and further clinical studies with a larger number of cases are needed to clarify the relationship between them.
机译:背景技术在过去的20年中,大量文献表明5-氟尿嘧啶(5-FU)的血浆浓度与大肠癌和头颈癌的临床反应和/或毒性相关,但相关信息很少关于长期生存的影响。在此,对日本食管鳞状细胞癌(ESCC)患者进行了基于基于5-FU /顺铂(CDDP)的放化疗的明确放疗(CRT)治疗后的5年随访,以及预后与5血浆浓度之间的关联评估FU。方法纳入了接受了最终的基于5FU / CDDP的CRT治疗的49例ESCC患者。一个疗程包括连续1-5天和8-12天以400 mg / m 2 /天的剂量连续输注5-FU,以40 mg / m 2 <在第1天和第8天/天,在第1天,第5天,第8天至12天和第15天至第19天以2 Gy /天的辐射量,在2周间隔后重复第二次疗程。 5-FU的血浆浓度通过高效液相色谱法在第3、10、38和45天的5:00 PM和第4、11、39和46天的5:00 AM进行测定。结果总体为期5年生存率为42.9%。年龄(P = 0.020),体重(P = 0.019)和疾病阶段(P = 0.048)影响生存期,生存期取决于治疗后1个月评估的临床反应(P = 0.001)。血浆5-FU浓度越高,临床反应越好(P = 0.043),并有延长生存期的趋势(P = 0.321)。结论用确定的基于5-FU / CDDP的CRT治疗后的长期存活可能取决于5-FU的血浆浓度,需要进一步的临床研究以进一步阐明它们之间的关系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号